Evidence map›Paper›PMID 16604302›Full record

Trial reportJournal of neural transmission (Vienna, Austria : 1996)2006

Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.

T Müller, C Erdmann, S Muhlack, D Bremen, H Przuntek, O Goetze, D Woitalla

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Journal of neural transmission (Vienna, Austria : 1996), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 51 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Review
  13. Article
  14. Bound, free, and total L-dopa measurement in plasma of Parkinson's disease patients.Journal of neural transmission (Vienna, Austria : 1996) · 2019
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Drug therapy in patients with Parkinson's disease.Translational neurodegeneration · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

T MüllerDepartment of Neurology, St. Josef Hospital, Ruhr University Bochum, Bochum, Germany. thomas.mueller@ruhr-uni-bochum.de
C Erdmann
S Muhlack
D Bremen
H Przuntek
O Goetze
D Woitalla
St. Josef-Hospital · DEOrion Corporation (United Kingdom) · GBRuhr University Bochum · DEUniversity Hospital of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Addition of the catechol-O-methyltransferase (COMT) inhibitor entacapone (EN) prolongs plasma metabolism of levodopa (LD). Objectives were to determine the clinical response after EN addition and the plasma degradation of LD and 3-O-methyldopa [3-OMD]. Not optimum treated hospitalised patients with Parkinson's disease received the same LD dosage on the first day only with carbidopa (CD) and on the second day with CD and EN (t.i.d.) within a standardised setting. We scored motor symptoms and measured LD- and 3-OMD levels on both days at fixed moments. Motor impairment significant better improved probably due to significant higher maximum concentrations [C(max)] and computed area under the curve values of LD levels during the LD/CD/EN condition. Time to C(max) of LD was significantly delayed after the first two LD/CD/EN intakes. An impact of EN on 3-OMD levels appeared. A possibly augmented LD absorption and a prolonged LD metabolism after EN supplementation may contribute to a more continuous LD delivery to the brain.

Indexed as

AdultAgedAntiparkinson AgentsArea Under CurveCarbidopaCatecholsChromatography, High Pressure LiquidFemaleHumansLevodopaMaleMiddle AgedMotor ActivityNitrilesParkinson DiseaseTyrosine3-methoxytyrosineAntiparkinson AgentsCarbidopaCatecholsentacaponeLevodopaNitrilesTyrosine

Identifiers

PMID16604302
OpenAlexW1996321703

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.